MDMD02
MUNIi002-A
General
Cell Line |
|
| hPSCreg name | MUNIi002-A |
| Cite as: | MUNIi002-A (RRID:CVCL_9S29) |
| Alternative name(s) |
MDMD02
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
CENSOi003-B (FB79R2c6, CENSOi258) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi005-A (FB76R2c5, CENSOi245) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi007-A (FB75R2c5, CENSOi255) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi001-B (FB78R2c2, CENSOi249) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi002-B (FB74R2c4, CENSOi261) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy |
| Last update | 18th October 2019 |
| User feedback | |
Provider |
|
| Generator |
Masaryk University (MUNI)
Contact:
Petr Dvorak's Laboratory |
| Owner | Petr Dvorak's Laboratory |
| Distributors | |
| Derivation country | Czech Republic |
External Databases |
|
| Cellosaurus | CVCL_9S29 |
| BioSamples | SAMEA6145612 |
| Wikidata | Q54907086 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 35-39 |
| Ethnicity | caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Family history | no related to case |
| Is the medical history available upon request? | mother - disease carrier, no related diseases known |
| Is clinical information available? | checked normal cardiac phenotype by Echocardiography and C-MRI |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Donor Relations |
|
| All cell lines of this donor's relatives |
Has son:
|
External Databases (Donor) |
|
| BioSamples | SAMEA6145613 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | Yes |
| Details on restriction to research project | |
| Does consent permit unforeseen future research, without further consent? | No |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
| Does consent permit access to medical records of the donor? | Yes |
| Please describe how access is provided: | |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | Yes |
| Contact data, institution, or website: | Masaryk University, Pediatric Neurology Clinic |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Ethics Committee, Medical faculty, Masaryk University |
| Approval number | 13/2012 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Ethics Committee, Medical faculty, Masaryk University |
| Approval number | 13/2012 |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Life Technologies |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
| Source cell type |
Synonyms
|
| Source cell origin |
A zone of skin that is part of a leg [Automatically generated definition].
Synonyms
|
| Source cell type (free text) | leg skin - tight |
| Age of donor (at collection) | 35-39 |
| Collected in | 2013 |
| Passage number reprogrammed | 3 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | morphology, alcaline phophatase, SSEA, Nanog |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Gelatin | ||||||||||||
| Feeder cells |
mouse embryonic fibroblast Cellfinder Ont Id: EFO_0004040 |
||||||||||||
| Passage method | Mechanically | ||||||||||||
| O2 Concentration | 20 % | ||||||||||||
| CO2 Concentration | 5 % | ||||||||||||
| Medium |
Other medium:
Base medium: Dulbecco`s modified Eagle medium (DMEM)/F12
Main protein source: Knock-out serum replacement Serum concentration: 15 % Supplements
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| Alkaline Phosphatase |
Yes |
|
||||
| NANOG |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
||||
| SSEA-3 |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
Differentiation Potency
In vitro spontaneous differentiation
In vitro directed differentiation
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
No
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.